Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Margaret S. Lucas"'
Autor:
Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers
Publikováno v:
Blood. 140:4166-4168
Autor:
Kerry A. Rogers, David M. Weiss, Ying Huang, Jennifer A. Woyach, Lynne V. Abruzzo, Nyla A. Heerema, Christin Banks, Allison Dean, Cara Grantier, Barbara L. Andersen, Margaret S. Lucas, Jeffrey A. Jones, Gerard Lozanski, Seema A. Bhat, John C. Byrd, Farrukh T. Awan, Kami J. Maddocks, Amy S. Ruppert, Thomas R. Valentine
Publikováno v:
J Clin Oncol
PURPOSE The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS This phase II study te
Autor:
Shane Sheredy, Mollie E. Moran, Jennifer A. Woyach, Jill Ford, Emily Desmond, Kristin Lynn Koenig, John C. Byrd, Emily Dotson, Seema A. Bhat, Shauna Iarocci, Margaret S. Lucas, Kerry A. Rogers, Ying Huang, Tracy Wiczer, Jeffrey A. Jones, Farrukh T. Awan
Publikováno v:
Blood Adv
Venetoclax has efficacy in patients relapsing after B-cell receptor pathway inhibitors (BCRis); however, because of the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up is required to attain the target dose. Patients relapsing after BCRis fr
Autor:
Weihong Chase, Joseph M. Flynn, Jeffrey A. Jones, Tzyy Jye Doong, Weiqiang Zhao, Kami J. Maddocks, Lynne V. Abruzzo, Dan Jones, Arletta Lozanski, Samantha McWhorter, Rose Mantel, Michael R. Grever, James S. Blachly, Farrukh T. Awan, Lisa L. Smith, Amy J. Johnson, Gerard Lozanski, Nyla A. Heerema, Kristie A. Blum, Amber Gordon, Samantha Jaglowski, Amy Lehman, Amy S. Ruppert, Leslie A. Andritsos, Daphne Guinn, Jennifer A. Woyach, Fan Ny, Kerry A. Rogers, Margaret S. Lucas, John C. Byrd, Joshua F. Coleman, Melanie E. Davis
Publikováno v:
Journal of Clinical Oncology. 35:1437-1443
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause r
Autor:
Weihong Chase, Kerry A. Rogers, Audrey M. Sigmund, Margaret S. Lucas, Farrukh T. Awan, John C. Byrd, Ying Huang, Kami J. Maddocks, Jennifer A. Woyach, Amy S. Ruppert, Michael R. Grever, Samantha Jaglowski, Leslie A. Andritsos, Fan Ny
Publikováno v:
Journal of Clinical Oncology. 36:7514-7514
7514Background: While it has been established that attainment of a complete response (CR) after chemoimmunotherapy improves progression free survival (PFS), this has not been proven with the BTK in...
Autor:
Beth Fischer, Margaret S. Lucas, Rosa Lapalombella, John C. Byrd, Amy J. Johnson, Farrukh T. Awan, Weihong Hu
Publikováno v:
Leukemia & Lymphoma. 51:27-38
The use of nucleoside analog-based chemo-immunotherapeutic regimens over the last decade has significantly improved outcomes in patients with chronic lymphocytic leukemia (CLL). Nonetheless, virtually all patients with CLL relapse from chemoimmmunoth
Autor:
Richard A. Miller, Margaret S. Lucas, Thomas S. Lin, Louie Naumovski, Carolyn Cheney, Philip Lecane, Mollie E. Moran, David M. Lucas, See-Chun Phan, John C. Byrd
Publikováno v:
Leukemia & Lymphoma. 50:1977-1982
Chronic lymphocytic leukemia (CLL) cells are susceptible to oxidative stress. The expanded porphyrin, motexafin gadolinium (MGd), reacts with intracellular reducing metabolites and protein thiols to generate reactive oxygen species (ROS). A phase II
Autor:
Jennifer A. Woyach, Jeffrey A. Jones, Mitch A. Phelps, Farrukh T. Awan, Yonghua Ling, Weihong Chase, Yao Jiang, John C. Byrd, Kami J. Maddocks, Joseph M. Flynn, Leslie A. Andritsos, Margaret S. Lucas, David M. Lucas, Ellen J. Sass, Sharon Waymer
Publikováno v:
Leukemialymphoma. 56(10)
The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid chronic lymphocytic leukemia (CLL) cel
Autor:
Elizabeth Garrett-Mayer, Ian W. Flinn, John C. Byrd, Louis F. Diehl, Steven N. Goodman, Michael R. Grever, Yvette L. Kasamon, Margaret S. Lucas
Publikováno v:
Clinical Cancer Research. 11:8413-8417
Purpose: Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts. In an attempt to preserve CD4 counts, we conducted a phase I, double-blind, placebo-controlle
Autor:
Margaret S. Lucas, Ian W. Flinn, David M. Lucas, Thomas S. Lin, John C. Byrd, J Sickler, Mollie E. Moran, Michael R. Grever, Pierluigi Porcu, Nyla A. Heerema
Publikováno v:
Leukemia. 19:1207-1210
Alemtuzumab (anti-CD52; Campath-1H) is effective in fludarabine-refractory chronic lymphocytic leukemia (CLL), but is associated with infection and early onset neutropenia. To reduce toxicity, filgrastim (G-CSF) was administered concurrently with ale